Dermatology · Aventura, FL
NPI
1336148535
Since 2005
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
21097 NE 27th Ct Ste 580
Aventura, FL, 33180
Phone (305) 692-8998
Groups this clinician bills Medicare through
Medicare paid, 2024
$85K
1,601 services
Medicare patients, 2024
319
Average age 76
Drug cost, 2024
$1.5M
564 prescriptions
Company payments, 2025
$39K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Barry I Resnik was code 99213 (office e&m - established), 324 times for 220 patients. In total Barry I Resnik billed 1,601 services in 54 codes, and Medicare paid $85K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-01-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 324 | 220 | $66.01 | $21K |
| 17003 Destruction Skin Lesion | Office | 232 | 39 | $5.08 | $1,178 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 156 | 34 | $0.74 | $116 |
| 11102 Skin Biopsy | Office | 88 | 75 | $72.35 | $6,367 |
| 99212 Office E&M - Established | Office | 69 | 55 | $39.59 | $2,732 |
| 17000 Destruction Skin Lesion | Office | 68 | 53 | $44.28 | $3,011 |
| 99214 Office E&M - Established | Office | 65 | 56 | $98.56 | $6,406 |
| 99203 Office E&M - New | Office | 52 | 52 | $86.26 | $4,485 |
| 96372 Injection Administration | Office | 51 | 21 | $11.06 | $564 |
| 11103 Skin Biopsy | Office | 28 | 22 | $41.64 | $1,166 |
| 11900 Skin | Office | 24 | 14 | $36.24 | $870 |
| 17262 Destruction Skin Lesion | Office | 21 | 20 | $118.69 | $2,492 |
| 99204 Office E&M - New | Office | 15 | 15 | $125.15 | $1,877 |
By year: 2022 $151K for 1,698 services; 2023 $78K for 1,550 services; 2024 $85K for 1,601 services.
Medicare prescription drug claims, 2024
In 2024, the drug Barry I Resnik prescribed most often to Medicare patients was Cosentyx Sensoready (2 Pens) (Secukinumab), with 53 prescriptions and refills. In total Barry I Resnik wrote 564 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Cosentyx Sensoready (2 Pens) Secukinumab | 53 | 53 | Under 11 | $709K |
| Triamcinolone Acetonide Generic | 49 | 53 | 41 | $321 |
| Ketoconazole Generic | 44 | 52 | 21 | $717 |
| Terbinafine Hcl Generic | 30 | 48 | 16 | $264 |
| Clindamycin Phosphate Generic | 29 | 31 | 11 | $648 |
| Cyclosporine Modified Cyclosporine, Modified | 19 | 23 | Under 11 | $4,482 |
| Gabapentin Generic | 18 | 19 | Under 11 | $531 |
| Sodium Chloride 0.9 % Sodium Chloride | 18 | 18 | Under 11 | $92.03 |
| Hydrocortisone Generic | 17 | 18 | Under 11 | $90.52 |
| Ertapenem Ertapenem Sodium | 17 | 17 | Under 11 | $15K |
| Prednisone Generic | 17 | 17 | 14 | $68.63 |
| Metronidazole Generic | 15 | 19 | Under 11 | $687 |
| Clobetasol Propionate Generic | 14 | 17 | 11 | $565 |
| Remicade Infliximab | 14 | 14 | Under 11 | $129K |
| Imiquimod Generic | 13 | 13 | 11 | $277 |
Brand drugs: - claims; generic drugs: 428 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Barry I Resnik $39K ($39K in general payments such as food, travel and fees) from 16 companies. The largest payer was Novartis Pharmaceuticals Corporation with $13K.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 12 | $13K |
| UCB, Inc. UCB.BR | 26 | $12K |
| Incyte Corporation INCY | 19 | $12K |
| Abbvie Inc. ABBV | 10 | $244 |
| Galderma Laboratories, L.P. GALD.SW | 4 | $153 |
| Janssen Biotech, Inc. JNJ | 4 | $152 |
| Smith+Nephew, Inc. SNN | 4 | $117 |
| LEO Pharma Inc. | 3 | $76.77 |
| Pfizer Inc. PFE | 3 | $68.04 |
| Lilly USA, LLC LLY | 2 | $65.25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.